THE Health dept has announced that several PBS drugs will be subject to price reductions on 01 Aug 2009, due to the first round of the new disclosure regime. The system, introduced as part of the PBS Reform package, gives the govt total transparency in PBS pricing, allowing it to achieve savings on behalf of taxpayers. Reductions, based on data collected from manufacturers during during 2008, will apply to the following medications:
- doxorubicin (down 63.54%)
- meloxicam (-22.46%)
- mitozantrone (-34.42%
- ondansetron (-15.37%)
The Pharmacy Guild welcomed the price cuts, with president Kos Sclavos saying it’s conservatively estimated the move will save the govt $13m a year in PBS outlays. However no reduction will apply to six other drugs subjected to price disclosure: amisulpride, fluconazole, fosinopril sodium.
Monday, February 2, 2009
Subscribe to:
Posts (Atom)
